Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin
- PMID: 30514595
- DOI: 10.1016/j.diagmicrobio.2018.10.020
Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin
Abstract
Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.
Keywords: Amikacin; Carbapenem-resistant Enterobacteriaceae; Meropenem; Polymyxin B; Time kill.
Copyright © 2018 Elsevier Inc. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
